Immunotherapies for hepatocellular carcinoma

Area of Science:

• Hepatology
• Medical Oncology
• Immunotherapy

Background:

• Hepatocellular carcinoma (HCC) incidence is rising globally, particularly in Western countries.
• Limited effective systemic treatments exist for advanced HCC, with traditional options reserved for early-stage disease.
• Existing treatments like Sorafenib and Lenvatinib offer marginal survival benefits and significant side effects.

Purpose of the Study:

• To review current and emerging systemic treatment strategies for advanced hepatocellular carcinoma (HCC).
• To discuss the advantages and disadvantages of novel immunotherapies in HCC treatment.
• To provide future perspectives on the evolving landscape of HCC systemic therapy.

Main Methods:

• Review of recent scientific literature and clinical trial data on advanced HCC treatments.
• Analysis of approved and investigational immunotherapies, including immune checkpoint inhibitors.
• Exploration of other immunotherapeutic approaches such as CAR T-cells, vaccines, and oncolytic viruses.

Main Results:

• The Atezolizumab/Bevacizumab combination has shown success and gained regulatory approval for first-line advanced HCC treatment.
• Several immune checkpoint inhibitors are in advanced clinical trials for HCC.
• Other immunotherapies are in early-stage development for advanced HCC.

Conclusions:

• Immunotherapy represents a significant advancement in treating advanced HCC, addressing an unmet clinical need.
• The field of HCC systemic therapy is rapidly evolving with promising novel agents.
• Continued research and clinical trials are crucial for optimizing future HCC treatment strategies.